OptiBiotix Health PLC Successful launch of products at Supply Side West

OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, and diabetes has announced the successful launch of its SlimBiome® and LPLDL® products at Supply Side West in Las Vegas, on 27-28 September 2017. The exhibition provided the opportunity to connect with 16,500 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries. The event also created the opportunity to meet with senior executives from existing corporate partners and potential new corporate partners, as well as distributors from Europe, the USA and Asia.

The Company recently obtained FDA registration for both its LPLDL® and SlimBiome® product ranges allowing it to present its products at Supply Side West as the first of a number of commercial steps to supply these functional ingredients to food, beverage, consumer healthcare and pharmaceutical partners for distribution and sale into the US market. LPLDL® was co-exhibited with Sacco, one of the largest suppliers of probiotic ingredients, whilst SlimBiome® was co-exhibited with specialty ingredients manufacturer, Cereal Ingredients. 

 

Both LPLDL® and SlimBiome® were extremely well received with high interest in the distribution and sale of these products from partners across Europe, Japan, India, Asia and the USA. Further updates will be provided as interest develops into commercial agreements but early outcomes from the exhibition include:-

1. Sacco have appointed Dr Lucio Lepera as Product Manager for LPLDL®. This is a significant financial commitment from Sacco, to support entry to the US probiotic market and extend the opportunities offered by LPLDL® into dairy applications to access the $35.5 billion probiotic dairy market.

2. Cereal Ingredients have incorporated SlimBiome® into their range of cereal based particulates and speciality ingredients. This technical innovation extends the application of SlimBiome® into bakery products (e.g. cookies, cakes and tortillas), breakfast cereals (puffs and flakes), crackers, toppings (e.g. salad, breakfast) as well as increasing the range of options for healthy snacks, yoghurts and cereal bars. This significantly extends the scale of the opportunity beyond weight management into the nutraceutical, health and wellbeing industry sectors.

Stephen O’Hara, CEO of OptiBiotix, commented: “We are extremely pleased with the very high level of interest from both national and multinational companies interested in our products and the opportunity to meet with senior US and Asian decision makers at Supply Side West. We are particularly pleased by the commitment shown by our partners who have invested significant financial resources in providing exhibition space, appointed and trained new personnel, and developed new products at their own cost, to support the commercialisation of our products. We believe this reflects the high level of confidence in the commercial potential of our products. As we build the range of applications and geographic scope of LPLDL® and SlimBiome® with new manufacturing and distribution partners; the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products. If successful, this low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products has the potential to cumulatively generate substantive revenues in the forthcoming years across all platforms.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Optibiotix Health Plc

    More articles like this

    Optibiotix Health Plc

    NutraIngredients Awards shortlist announced

    NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10

    Optibiotix Health Plc

    OptiBiotix Health plc Launch of Slimbiome® in Nutri-bites®

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural

    Optibiotix Health Plc

    OptiBiotix Health PLC OptiBiotix Capital Reorganisation

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in

    Optibiotix Health Plc

    Optibiotix Health PLC In a Strong Position

    Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.

    Optibiotix Health Plc

    Functional weight loss ingredient, SlimBiome brought to US

    OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to

    Optibiotix Health Plc

    SlimBiome® – Supporting hunger-free weight management

    Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake

    Optibiotix Health Plc

    OptiBiotix Health PLC Proposed Directorate Changes

    OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will

    Optibiotix Health Plc

    Optibiotix Health PLC on Kelloggs’ Sugar Levels Cut

    Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts:   “We are really